Derilife - the highly active corticosteroid of local action which is applied the adult to elderly people and children is more senior than 1 year only for short-term treatment of rather steadier inflammatory manifestations of a steroidchuvstvitelny dermatosis which are insensitive to less active corticosteroids.

Such diseases are:

• psoriasis (except for widespread blyashechny psoriasis);
• dermatosis which is difficult responding to treatment;
red flat deprive of
• ;
• diskoidny lupus erythematosus;
• other diseases of skin which are not responding to treatment by less active corticosteroids.

Structure

• active ingredient: klobetazol;
0.5 mg contain
• 1 g of cream klobetazol propionate;
• other components: white wax; propylene glycol; chlorcresol; polyethyleneglycol (macrogoal) cetostearyl ether; the castor oil polyethoxylated, hydrogenated; polyethyleneglycol (macrogoal) hydroxystearate; cetostearyl alcohol; water is purified.

Contraindication

• Hypersensitivity to active ingredient and/or excipients of medicine.
• Not treated infections of skin.
• Rozatsea.
• Ordinary eels.
• Naggers without inflammation.
• Perianal and genital itching.
• Perioral dermatitis.
• Dermatosis at children till 1 year, including dermatitis and diaper rashes.

Route of administration

Klobetazol propionate belongs to the class of the most strong local corticosteroids (group IV), and prolonged use can result in serious undesirable effects. If treatment by a local corticosteroid is clinically justified after 4 weeks, it is necessary to consider less powerful medicament of corticosteroids. Repeated, but short courses of a klobetazol of propionate can be used for control of aggravations.

for topical (skin) administration.

for treatment of the damp and becoming wet sites of skin. Cream it is soft to p to put

with a thin layer, covering all affected areas of skin, 1 or 2 times a day before emergence of improvement of clinical manifestations (at the good response to treatment the improvement is reached for several days), then to reduce the frequency of use or to change to less powerful drug. After each putting cream wait certain time before full absorption before applying emollient. In case of deterioration or lack of improvement of clinical manifestations within 2-4 weeks the diagnosis and treatment should be revised.

Maximum week dose should not exceed 50 g

Feature of use

Use during pregnancy or feeding by a breast

Data on use of a topical klobetazol to pregnant women are limited.

Should use the minimum quantity of medical means during the minimum term of treatment.

. Medicine can be applied during feeding by a breast, only if the expected advantage for the woman exceeds risk for the child.

Medicine is contraindicated to

for treatment of a dermatosis, including dermatitis at children till 1 year.

Ability to influence speed of response at control of motor transport or other mechanisms

Researches on studying such influence were not conducted by

. Considering a profile of side reactions of a klobetazol, influence on speed of response at control of motor transport or other mechanisms is not expected.

Overdose

At usual use in enough for emergence of system effect. Probability of emergence of acute overdose is very insignificant, however at chronic overdose or the wrong use there can be signs of a giperkortizolizm.

Treatment.

At overdose should be cancelled gradually by reduction of frequency of putting cream or its substitution with less powerful corticosteroid, considering risk of emergence of glucocorticosteroid insufficiency.

according to a clinical condition of the patient or according to national recommendations about treatment of poisonings in the presence.

Side reactions

Infection and invasion: very seldom – opportunistic infections.

from the immune system: very seldom – local hypersensitivity.

from an endocrine system: very seldom – oppression gipotalamo - a hypophysial and adrenal system: cushingoid signs (for example, a crescent-shaped face, the central obesity), a delay of increase in mass of a body/growth at children, osteoporosis, glaucoma, a hyperglycemia/glucosuria, increase in weight body/obesity, reduction of level of endogenous cortisol, an alopecia, fragility of hair.

from organs of sight: frequency is unknown – disturbance of clearness of sight.

Interaction with other medicines and other types of interactions

Was shown that simultaneous use with the medicaments inhibiting CYP3A4 (for example, ritonavir, itrakonazol), slows down metabolism of corticosteroids that can render the increased system effect. As far as such interaction is clinically significant, depends on a dose, a way of introduction of a corticosteroid and power of CYP3A4 inhibitor.

to Store

at a temperature not over 25 ºС out of children's reach.